| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/30/2002 | US6380184 For increased production of wool, milk, and meat by treating animals with therapeutically effective amount of compound |
| 04/30/2002 | US6380170 Nucleic acid construct for the cell cycle regulated expression of structural genes |
| 04/30/2002 | US6380163 Containing osmotic agent with an additional osmotic agent such as dextrose |
| 04/30/2002 | US6379931 Derived from spacer reagent 3-(4,4'-dimethoxytrityloxy)propane-1-((2-cyanoethyl)-(n,n-diisopropyl)) -phosphoramidite; use treating viral and rna-mediated diseases such as hiv |
| 04/30/2002 | CA2177823C Poly-beta-1-->4-n-acetylglucosamine |
| 04/30/2002 | CA2093819C Platelet adhesion inhibitor |
| 04/25/2002 | WO2002033100A2 Regulation of human adenylate cyclase, type iv |
| 04/25/2002 | WO2002033099A2 Human kinases |
| 04/25/2002 | WO2002033089A2 Ixodes scapularis tissue factor pathway inhibitor |
| 04/25/2002 | WO2002032958A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors |
| 04/25/2002 | WO2002032957A1 Peg-modified erythropoietin |
| 04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 04/25/2002 | WO2002032461A2 Protein c or activated protein c-like molecules |
| 04/25/2002 | WO2002032447A2 Cell damage inhibitor |
| 04/25/2002 | WO2002032446A2 Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils |
| 04/25/2002 | WO2002032445A2 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | WO2002032439A1 A herbal pharmaceutical composition and its process |
| 04/25/2002 | WO2002032438A1 Pharmaceutical composition treating gynecological blood stasis diseases, cardio and cerebral vascular diseases, respiratory diseases and the like |
| 04/25/2002 | WO2002032435A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 04/25/2002 | WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | WO2002032406A2 Methods and products related to pulmonary delivery of polysaccharides |
| 04/25/2002 | WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/25/2002 | WO2001096366A3 Dipeptide inhibitors for the blood-clotting factor xa |
| 04/25/2002 | WO2001082874A3 A medicinal aerosol formulation |
| 04/25/2002 | WO2001047533A3 INHIBITION OF GSK-3$g(b) |
| 04/25/2002 | WO2001042471A3 Polypeptides and polynucleotides encoding same |
| 04/25/2002 | US20020049410 Indwelling heat exchange catheter and method of using same |
| 04/25/2002 | US20020049409 Indwelling heat exchange catheter and method of using same |
| 04/25/2002 | US20020049322 Quinoline and quinazoline compounds useful in therapy |
| 04/25/2002 | US20020049301 For therapy of cancer, diabetes, obesity, diseases of the central nervous system, inflammatory disorders, autoimmune dieseases cardiovascular diseases, for generating antibodies |
| 04/25/2002 | US20020049244 Treatment of disease or disease symptoms mediated by eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE) a potent constrictor of renal, cerebral and skeletal muscle arterioles |
| 04/25/2002 | US20020049234 Inhibitors of factor Xa; for example 3-(4-tert-butylbenzoyl)amino-N-(4-methoxyphenyl)-2-thiophenecarboxamide |
| 04/25/2002 | US20020049231 S(-)-3-aminothalidomide; treating wide variety of diseases including diabetic retinopathy |
| 04/25/2002 | US20020049220 Substituted azoles |
| 04/25/2002 | US20020049194 A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist |
| 04/25/2002 | US20020049183 Phospholipids, espeically phosphatidylethanolamines, covalently bound to physiologically acceptable monomers or polymers. |
| 04/25/2002 | US20020049161 Especially Fe(III) saccharate and gluconate; treatment of hemodialysis patients. |
| 04/25/2002 | US20020048794 Polypeptides for use in the diagnosis and treatment of skin disorders, cancer, vision and demyelination defects, inflammation, glomerculonephritis, Kaposi's sarcoma, angiogenesis, sarcoidosis, osteoarthritis and aneurysm |
| 04/25/2002 | US20020048271 Methods and composition for restoring conformational stability of a protein of the p53 family |
| 04/25/2002 | US20020046967 Blood centrifuge cup having a replaceable compartment for filter support |
| 04/25/2002 | DE10050723A1 New N-substituted amino acid derivatives for treating thromboembolic diseases e.g. thrombosis, myocardial infarct, arteriosclerosis, inflammation, stroke, angina, restenosis are factor Xa inhibitors |
| 04/25/2002 | DE10050334A1 Composition comprising stem cells and CD6-depleted stem cells, useful for inducing transplant tolerance and for treatment, especially of leukemia, administered separately |
| 04/25/2002 | CA2453140A1 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | CA2426487A1 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | CA2426381A1 Cell damage inhibitor |
| 04/25/2002 | CA2425963A1 Human kinases |
| 04/25/2002 | CA2425221A1 Protein c or activated protein c-like molecules |
| 04/25/2002 | CA2423469A1 Methods and products related to pulmonary delivery of polysaccharides |
| 04/24/2002 | EP1199368A2 Use of adenoviral e4 reading frames to improve expression of a gene of interest |
| 04/24/2002 | EP1199081A1 Use of inhibition of a growth arrest-specific gene (gas6) function or of a gas6 receptor for preventing and treating a thromboembolic disease |
| 04/24/2002 | EP1199080A2 Co-administration of interleukin-3 mutants with colony stimulating factors |
| 04/24/2002 | EP1199076A2 Medicament containing tocotrienol as active component |
| 04/24/2002 | EP1198568A1 Compositions and methods for the treatment of immune related diseases |
| 04/24/2002 | EP1198563A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 04/24/2002 | EP1198560A2 Mammalian adhesion protease peptides |
| 04/24/2002 | EP1198255A1 Identification of compounds that modify transcriptional responses to hypoxia |
| 04/24/2002 | EP1198246A2 Methods for preventing or attenuating pathoangiogenic conditions by using the gbs-toxin (cm101) receptor as a vaccine |
| 04/24/2002 | EP1198242A1 Autologous thrombin |
| 04/24/2002 | EP1198241A1 Novel proteins |
| 04/24/2002 | EP0765126B1 Therapeutic food composition and method to diminish blood sugar fluctuations |
| 04/24/2002 | EP0714299B1 Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
| 04/24/2002 | CN1346403A Method and apparatus or maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| 04/24/2002 | CN1346370A Polypeptides involved in immune response |
| 04/24/2002 | CN1346369A Method and compositions for the prevention and treatment of anamia |
| 04/24/2002 | CN1346350A Compound which inhibiti leukocyte adhesion mediated by VLA-4 |
| 04/24/2002 | CN1346344A Substituted 2-aminobenzamide caspase ihibitors and the use thereof |
| 04/24/2002 | CN1346292A Treatment of thrombosis by combined useof a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA) a gpII/IIIA antagonist, low molecular weight heparin or heparin |
| 04/24/2002 | CN1346286A Methods and compositions for use in perfusion applications |
| 04/24/2002 | CN1346272A Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 04/23/2002 | US6376665 Antiarthritic agents, antiinflammatory agents |
| 04/23/2002 | US6376648 Polypeptides |
| 04/23/2002 | US6376519 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2 |
| 04/23/2002 | US6376517 For treating vision loss, preventing vision degeneration, and promoting vision regeneration (?neopsis?) |
| 04/23/2002 | US6376515 Benzamides and related inhibitors of factor Xa |
| 04/23/2002 | US6376499 Piperazine-amide compound with anticoagulant activity |
| 04/23/2002 | US6376463 Modified factor VIII |
| 04/23/2002 | US6376242 Reduce the number of circulating platelets to low or below normal levels. |
| 04/23/2002 | US6375975 Pharmaceutical compositions for buccal and pulmonary application |
| 04/23/2002 | CA2223403C Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds |
| 04/23/2002 | CA2191714C Therapeutic food composition and method to diminish blood sugar fluctuations |
| 04/23/2002 | CA2069296C Combination preparation with antithrombotic action |
| 04/23/2002 | CA2004127C Novel aminobenzoates |
| 04/18/2002 | WO2002031134A2 Novel serine protease genes related to dppiv |
| 04/18/2002 | WO2002031115A2 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | WO2002030938A1 Benzhydryl derivatives |
| 04/18/2002 | WO2002030908A1 Inhibitors of protein kinases |
| 04/18/2002 | WO2002030888A2 Tricyclic compounds and uses thereof |
| 04/18/2002 | WO2002030884A2 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030882A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030880A2 N-substituted amino acid derivatives (factor xa inhibitors) |
| 04/18/2002 | WO2002030863A2 Ether compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030860A2 Ketone compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | WO2002030470A1 Methods and compositions for nucleic acid delivery |
| 04/18/2002 | WO2002030459A1 Use of cd28-specific monoclonal antibodies for stimulating blood cells that lack cd28 |
| 04/18/2002 | WO2002030433A2 Use of stem cells and cd6-depleted stem cells for inducing tolerance of allogenic transplants and/or for treating leukaemia |
| 04/18/2002 | WO2002030409A2 Methods for the treatment of a traumatic central nervous system injury |
| 04/18/2002 | WO2002030353A2 NF-λB INHIBITORS |
| 04/18/2002 | WO2002030190A1 Method of inactivating viral particles in a blood product |
| 04/18/2002 | WO2002012210A9 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 04/18/2002 | WO2002011742A3 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |